Exact Sciences (EXAS) Reports Q3 Loss, Lags Revenue Estimates
Portfolio Pulse from
Exact Sciences (EXAS) reported a Q3 loss of $0.21 per share, missing the Zacks Consensus Estimate of a $0.20 loss. This is a decline from break-even earnings per share a year ago.

November 05, 2024 | 11:45 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Exact Sciences reported a Q3 loss of $0.21 per share, missing the consensus estimate of a $0.20 loss, and showing a decline from last year's break-even earnings.
The reported loss per share of $0.21 was worse than the expected $0.20 loss, indicating a negative surprise. Compared to last year's break-even, this suggests a deterioration in financial performance, likely leading to short-term negative pressure on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100